- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- TVB-009, Prolia®
- Combination Product
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 60 Years to 90 Years · Female only
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–59
of 59
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- GA 20 mg/mL, GA 40 mg/mL
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 35
- States / cities
- Cullman, Alabama • Gilbert, Arizona • Phoenix, Arizona + 31 more
- Conditions
- Non-radiographic Spondyloarthritis
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Fullerton, California + 15 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab)
- Drug · Other · Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 7
- States / cities
- Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- secukinumab
- Biological
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Volunteers
- Interventions
- Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • Grayslake, Illinois • Las Vegas, Nevada + 1 more
- Conditions
- Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Interventions
- VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 17
- States / cities
- Anniston, Alabama • Fullerton, California • La Palma, California + 14 more
- Conditions
- Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
- Interventions
- secukinumab 300 mg Q4W, secukinumab 300 mg Q2W, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Thousand Oaks, California • Cromwell, Connecticut + 12 more
- Conditions
- Acute Gouty Arthritis
- Interventions
- Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 69
- States / cities
- Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
- Interventions
- FYB201 0.5 mg (0.05 mL of 10 mg/mL)
- Drug
- Lead sponsor
- Formycon AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Campbell, California • Long Beach, California • Hagerstown, Maryland + 1 more
- Conditions
- Autoimmunity, Inflammation
- Interventions
- Secukinumab s.c. injection
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 100 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 28
- States / cities
- Fullerton, California • La Mesa, California • San Leandro, California + 25 more